SS-0350 is under clinical development by Softox Solutions and currently in Phase I for Bacterial Infections. According to GlobalData, Phase I drugs for Bacterial Infections have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SS-0350’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SS-0350 is under development for the treatment of bacterial infections in wounds. The therapeutic candidate is a water-based formulation containing stabilized hypochlorous acid (HOCl) in acetic buffer. It is administered through topical route in the form of solution.
Softox Solutions overview
Softox Solutions (Softox), is a medical technology company with a focus on developing antiseptic agents for the treatment of skin infections. The company provides non-toxic antimicrobial solution which is effective against bacteria in biofilms including antibiotic resistant bacteria like MRSA, fungi, viruses and spores. Softox is developing products for the treatment of infections in acute or chronic wounds and eczema. It also aims to develop products for oral health. The company works in collaboration with scientists and clinicians from the University of Copenhagen and Lund Hospital in Denmark, to develop antimicrobial technology. Softox is headquartered in Oslo, Norway.
For a complete picture of SS-0350’s drug-specific PTSR and LoA scores, buy the report here.